Skip to content

Jewel ACL Post Market Clinical Follow Up Study

The JewelACL Post Market Clinical Follow Up Study - Multicentre Study of at Least 5 Years Follow up, Looking at Clinical Outcomes in Patients Treated With the JewelACL for Anterior Cruciate Ligament (ACL) Reconstruction

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04580290
Enrollment
120
Registered
2020-10-08
Start date
2020-10-02
Completion date
2021-04-09
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterior Cruciate Ligament Injuries

Brief summary

The objective of the study is to assess re-rupture rates and patient outcomes from subjects with at least 5 year follow up, treated with the JewelACL device for ACL reconstruction. The impact of fixation type and autograft augmentation will also be assessed. All adverse events related to the JewelACL device will be recorded. This study is Sponsored by Xiros.

Interventions

DEVICEJewelACL

The JewelACL is a polyester scaffold for anterior cruciate ligament (ACL) reconstruction

Sponsors

Xiros Ltd
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age more than 18 years * Patients previously implanted with the JewelACL for Anterior Cruciate Ligament (ACL) reconstruction (Primary JewelACL cases only, no revision cases)

Exclusion criteria

* Age less than 18 years * Any implantations for non-indicated conditions, as stated in the Instructions For Use Instructions for use (IFU) * Revision cases

Design outcomes

Primary

MeasureTime frameDescription
Occurrence of Re-rupturesFive YearNumber of participants with re-rupture that were implanted with the jewelACL device for ACL reconstruction

Countries

Poland

Participant flow

Participants by arm

ArmCount
Jewel ACL Only
Subjects who received only the JewelACL
88
JewelACL + Autograft (Hybrid)
Subjects who received the JewelACL + Autograft (hybrid)
32
Total120

Baseline characteristics

CharacteristicJewel ACL OnlyJewelACL + Autograft (Hybrid)Total
Age, Continuous32.3 years
STANDARD_DEVIATION 10.1
32.2 years
STANDARD_DEVIATION 11.4
32.3 years
STANDARD_DEVIATION 10.4
Cause of ACL failure
Not available
10 Participants4 Participants14 Participants
Cause of ACL failure
Other Accident
3 Participants4 Participants7 Participants
Cause of ACL failure
Sports Injury
72 Participants23 Participants95 Participants
Cause of ACL failure
Traffic Accident
3 Participants1 Participants4 Participants
Femoral Fixation
Endobutton TightRope Arthrex
0 Participants1 Participants1 Participants
Femoral Fixation
Linvatec XO
0 Participants1 Participants1 Participants
Femoral Fixation
Medgal Screw
86 Participants29 Participants115 Participants
Femoral Fixation
S+N EndoButton
2 Participants1 Participants3 Participants
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
17 Participants5 Participants22 Participants
Sex: Female, Male
Male
71 Participants27 Participants98 Participants
Sports participation-yes66 Participants24 Participants90 Participants
Tibial Fixation Medgal screw88 Participants32 Participants120 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 880 / 32
other
Total, other adverse events
1 / 880 / 32
serious
Total, serious adverse events
5 / 881 / 32

Outcome results

Primary

Occurrence of Re-ruptures

Number of participants with re-rupture that were implanted with the jewelACL device for ACL reconstruction

Time frame: Five Year

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
JewelACL OnlyOccurrence of Re-ruptures5 Participants
JewelACL + Autograft (Hybrid)Occurrence of Re-ruptures1 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026